Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chuikyo Subcommittee to Form Consensus on Drug Prices by Autumn
March 26, 2001
- Mucosal Influenza Vaccine More Effective than Conventional Vaccines
March 26, 2001
- Mochida to Restructure Its Production System
March 26, 2001
- Chuikyo Subcommittee Starts Discussions for Next Revision of Medical Fees
March 26, 2001
- Draft Guidelines on Genetic Testing Compiled by Eight Societies
March 26, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 26, 2001
- 850 Questions Received Regarding Evidence for Off-label Use of Drugs
March 26, 2001
- Gene Therapy for Buerger's Disease to Be Approved Shortly
March 26, 2001
- Applications Aimed at Preventing Accidents to Be Approved Quickly
March 26, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 26, 2001
- LDP Convention Calls For Radical Reform in 2002
March 26, 2001
- MEDICAL DEVICE NEWS IN BRIEF
March 26, 2001
- DPJ Starts Discussions on Healthcare Reform
March 26, 2001
- OTC NEWS IN BRIEF
March 26, 2001
- Medical Institution Information System to Go into Operation in Osaka
March 26, 2001
- Kemporen Members' Ordinary Loss to Increase to \490.4 Bil.
March 26, 2001
- PMSB to Publish Criteria for Disclosure or Non-disclosure of Information
March 26, 2001
- Aiming at \30 Billion Sales in 2005: Mr Strenger of Aventis Behring
March 26, 2001
- More Patents Exported than Imported in Pharmaceutical Field
March 26, 2001
- Roche's Herceptin Marks Step toward Tailor-made Medicine
March 26, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…